Functional analysis of new biomarkers (Runx3, EZH2) in Gastroesophageal junction cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461981
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Nagasaki University
• Principal Investigator: KUNIZAKI Masaki 長崎大学, 病院(医学系), 助教 (10533747)
• Research Collaborator: HIDAKA Shigekazu 長崎大学, 病院(医学系), 講師 (30380885) ; NAGAYASU Takeshi 長崎大学, 医歯薬学総合研究科(医学系), 教授 (80284686)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 食道胃接合部癌 / EZH2

Outline of Final Research Achievements

Identifying useful biomarkers were essential to select optimal therapeutic strategies for cancer. Quantitative real-time PCR analysis revealed higher expression of EZH2 in clinical gastric cancer tissues than in corresponding non-neoplastic tissues, and we comfirmed that a wide range of cancers also overexpress EZH2, using cDNA microarray analysis. Immunohistochemical analysis showed positive staining (>50%) for EZH2 in 77 of 97 cases of gastric cancer. We could not find elevated expression of EZH2 to be associated with poor prognosis for patients with gastric cancer (P=0.670). Our study has demonstrated that combination of s-p53Ab and other tumor markers can serve as a useful biomarker set of gastrointestinal cancer and should be incorporated into traditional clinical and pathologic variables to complement outcome prediction of gastrointestinal cancer patients after treatment.

Free Research Field

腫瘍外科学